MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3% – Time to Sell?

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) traded down 4.3% during mid-day trading on Friday . The stock traded as low as $12.42 and last traded at $12.6150. 208,023 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 1,500,665 shares. The stock had previously closed at $13.18.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Guggenheim reduced their target price on MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 30th. Wedbush cut their price objective on shares of MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating for the company in a research report on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $10.00 price target (down previously from $67.00) on shares of MoonLake Immunotherapeutics in a report on Monday, September 29th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $7.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 1st. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of “Hold” and an average target price of $30.25.

MoonLake Immunotherapeutics Stock Performance

The company has a 50-day moving average price of $12.79 and a two-hundred day moving average price of $32.83. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $800.95 million, a P/E ratio of -3.75 and a beta of 1.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period in the previous year, the firm posted ($0.56) earnings per share. On average, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the sale, the insider owned 72,908 shares in the company, valued at approximately $1,099,452.64. This trade represents a 64.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the transaction, the chief executive officer directly owned 2,948,577 shares of the company’s stock, valued at $44,464,541.16. The trade was a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 402,908 shares of company stock valued at $5,987,162 over the last 90 days. Company insiders own 12.02% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter valued at $94,000. Cubist Systematic Strategies LLC bought a new position in MoonLake Immunotherapeutics in the first quarter valued at $970,000. Advisors Asset Management Inc. raised its position in MoonLake Immunotherapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company’s stock valued at $157,000 after purchasing an additional 1,803 shares in the last quarter. Granahan Investment Management LLC raised its position in MoonLake Immunotherapeutics by 4.2% during the first quarter. Granahan Investment Management LLC now owns 142,220 shares of the company’s stock valued at $5,557,000 after purchasing an additional 5,782 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 3,343.2% in the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock worth $13,453,000 after purchasing an additional 334,320 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.